Clinical Trial Update: A Single Arm Phase II Trial in p16-positive Oropharynx Cancer of Selective Dose De-escalation of nodAl VolumEs at Minimal Risk and Primary Site Disease (SAVED) [Phase 2]

View source ↗

Summary

A single-arm Phase II trial (SAVED) in p16-positive oropharyngeal cancer evaluating selective dose de-escalation of nodal and primary-site radiation; the study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Head and Neck Squamous Cell Carcinoma
• Hpv-positive Oropharyngeal Squamous Cell Carcinoma
• Oropharyngeal Cancer
• Oropharyngeal Squamous Cell Carcinoma

Snippet

Sponsor: University of Maryland, Baltimore | Conditions: Head and Neck Cancer, Head and Neck Squamous Cell Cancer | Phase 2 | Status: NOT_YET_RECRUITING